Hepatitis B virus genotype B and high expression of interferon alpha receptor β subunit are associated with better response to pegylated interferon alpha 2a in Chinese patients with chronic hepatitis B infection

Hepatitis Monthly

Volumn 12, Issue 5, 2012, Pages 96-101

  Fan, He Bin ^a   Guo, Ya Bin ^b   Zhu, You Fu ^b   Chen, An Shen ^a   Zhou, Mu Xiu ^a   Li, Zhi ^a   Xu, Li Tong ^a   Ma, Xiao Ju ^a   Yan, Fu Ming ^a  

^a The People's Liberation Army 161 Hospital   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic; Hepatitis B; Human; IFNAR2 protein; Peginterferon alfa 2a

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON RECEPTOR; HEPATITIS B (E) ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INTERFERON ALPHA RECEPTOR BETA SUBUNIT; PEGASUS; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ARTICLE; CHINESE; DEPRESSION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; IRRITABILITY; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RELAPSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SERODIAGNOSIS; SIDE EFFECT; THYROIDITIS; TREATMENT RESPONSE;

EID: 84862609374     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6173     Document Type: Article

References (27)

1. Lu FM, Zhuang H. Prevention of hepatitis B in China: achievements and challenges. Chin Med J (Engl). 2009;122(24):2925-7.
2. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375-86.
3. Hui AY, Chan HL, Cheung AY, Cooksley G, Sung JJ. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005;22(6):519-28.
4. Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, et al. The Efficacy and Tolerability of Pegylated Interferon-alpha-2a in Chronic Hepatitis B: A Multicenter Clinical Experience. J Gastroenterol Hepatol. 2011:[Epub ahead of print].
5. Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol. 2011;26(10):1527-35.
6. Tian Y, Chen WL, Ou JH. Effects of interferon-alpha/beta on HBV replication determined by viral load. PLoS Pathog. 2011;7(7):e1002159.
7. Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther. 2011;16(5):629-37.
8. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5(8):890-7.
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431-5.
10. Sugauchi F, Kumada H, Sakugawa H, Komatsu M, Niitsuma H, Watanabe H, et al. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin Infect Dis. 2004;38(9):1222-8.
11. Tanaka Y, Orito E, Yuen MF, Mukaide M, Sugauchi F, Ito K, et al. Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. Hepatol Res. 2005;33(3):216-24.
12. Zeng GB, Wen SJ, Wang ZH, Yan L, Sun J, Hou JL. A novel hepatitis B virus genotyping system by using restriction fragment length polymorphism patterns of S gene amplicons. World J Gastroenterol. 2004;10(21):3132-6.
13. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350(11):1118-29.
14. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol. 2002;83(Pt 8):2059-73.
15. Olinger CM, Jutavijittum P, Hubschen JM, Yousukh A, Samountry B, Thammavong T, et al. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis. 2008;14(11):1777-80.
16. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000;81(Pt 1):67-74.
17. Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol. 2008;82(11):5657-63.
18. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol. 2011;26 (Suppl 1):123-30.
19. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002;36(6):1425-30.
20. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296(5573):1653-5.
21. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918-21.
22. Gong QM, Kong XF, Yang ZT, Xu J, Wang L, Li XH, et al. Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. J Viral Hepat. 2009;16(9):674-80.
23. Ishimura N, Fukuda R, Fukumoto S. Relationship between the intrahepatic expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases. J Gastroenterol Hepatol. 1996;11(8):712-7.
24. Ferreira PR, Tenore Sde B. Response predictors to treatment with pegylated interferon in chronic hepatitis B. Braz J Infect Dis. 2010;14(5):519-25.
25. Fujiwara D, Hino K, Yamaguchi Y, Ren F, Satoh Y, Korenaga M, et al. Hepatic expression of type I interferon receptor for predicting response to interferon therapy in chronic hepatitis C patients: a comparison of immunohistochemical method vs. competitive polymerase chain reaction assay. Hepatol Res. 2003;25(4):377-84.
26. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-39.
27. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigennegative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37(4):756-63.